Four Chinese Companies Rise in Hong Kong Debuts

Dow Jones
03/30
 

By Megan Cheah

 

Four companies made their trading debuts in Hong Kong on Monday, underscoring strong interest for fundraising in the city's capital markets.

The companies collectively raised around 4.19 billion Hong Kong dollars, equivalent to US$534.9 million, in net proceeds.

Shares of Epiworld International, which makes a type of silicon carbide wafer used in semiconductor devices, jumped as much as 44% to HK$110.00, before paring gains to HK$104.90.

The company's initial public offering price was set at HK$76.26 each. Epiworld raised the most out of the four IPOs, netting HK$1.56 billion in net proceeds through its offering of 21.5 million shares.

Collaborative robot maker Guangdong Huayan Robotics' stock rose as much as 27% to HK$21.52 from its IPO price of HK$17.00. It raised around HK$1.48 billion in net proceeds.

Meanwhile, shares of both Hangzhou Diagens Biotechnology, a developer of medical-imaging products, and Shandong Extreme Vision Technology, which manufactures artificial-intelligence computer-vision solutions, more than doubled in their trading debuts.

Diagens Biotechnology raised HK$719.8 million in net proceeds, while Extreme Vision's net proceeds came in at HK$434.4 million.

A fifth company, Beijing Tong Ren Tang Healthcare Investment, was also set to debut Monday, but pulled its offering, citing factors including prevailing market conditions.

The flurry of activity signals that Chinese companies are still flocking to Hong Kong for fundraising, setting the city up for another banner year. According to Hong Kong's exchange operator, 119 new listings in 2025 raised HK$286.9 billion, more than tripling the previous year's total.

 

Write to Megan Cheah at megan.cheah@wsj.com

 

(END) Dow Jones Newswires

March 30, 2026 02:30 ET (06:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10